**Beyond premature ovarian insufficiency: Staging reproductive aging in adolescent and young adult cancer survivors**

*Medica, ACO, et al.*

**Supplemental Table: Window Study participants by eligibility for the current analysis.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Participant Characteristicsa** | **Total****(N=722)** | **Ineligible****(N=384)** | **Eligible****(N= 338)** | **P-value** |
| **Demographics** |
| **Age at enrollment, mean (SD)** | 33.3 (4.7) | 32.6 (4.7) | 34.1 (4.6) | <0.01 |
|  **18-24**  | 41 (6.6) | 22 (5.7) | 19 (5.6) | <0.01 |
|  **25-30** | 171(27.5) | 112 (29.2) | 59 (17.5) |  |
|  **31-35** | 175 (28.2) | 151 (39.3) | 124 (36.8) |  |
|  **36-40** | 234 (37.7) | 99 (25.8) | 135 (40.1) |  |
| **Race** |  |  |  |  |
|  **Black** | 23 (3.2) | 13 (3.4) | 10 (3.0) | 0.57 |
|  **White** | 536 (74.2) | 292 (76.0) | 244 (72.2) |  |
|  **Asian** | 52 (7.2) | 26 (6.8) | 26 (7.7) |  |
|  **Mixed race** | 111 (15.4) | 53 (13.8) | 58 (17.2) |  |
| **Hispanic** | 142 (19.7) | 72 (18.8) | 70 (20.7) | 0.76 |
| **BMI** |  |  |  |  |
|  **< 18.5** | 21 (3.0) | 12 (3.2) | 9 (2.7) | 0.99 |
|  **18.5-24.9** | 332 (47.3) | 177 (47.3) | 155 (47.3) |  |
|  **25-29.9** | 171 (24.4) | 91 (24.3) | 80 (24.4) |  |
|  **> 30** | 178 (25.4) | 94 (25.1) | 84 (25.6) |  |
| **Smoking current** | 34 (4.7) | 22 (5.7) | 12 (3.6) | 0.17 |
| **Cancer Characteristics** |
| **Age at diagnosis, mean (SD)** | 26.1 (5.6) | 26.0 (5.8) | 26.2 (5.4) | 0.69 |
|  **<18** | 222 (30.8) | 111 (30.0) | 111 (32.9) | 0.40 |
|  **18-24** | 77 (10.7) | 47 (12.3) | 30 (8.9) |  |
|  **25-30** | 252 (35.0) | 133 (34.7) | 119 (35.3) |  |
|  **31-35** | 169 (23.5) | 92 (24.0) | 77 (22.9) |  |
| **Cancer type**  |  |  |  |  |
| **Breast** | 202 (28.0) | 125 (32.6) | 77 (22.8) | 0.01 |
| **Leukemia, lymphoma** | 235 (32.5) | 112 (29.2) | 123 (36.4) |  |
| **Cervix, uterus, ovary** | 63 (8.7) | 40 (10.4) | 23 (6.8) |  |
| **Intestines stomach, gallbladder** | 22 (3.0) | 9 (2.3) | 13 (3.9) |  |
| **Bone/soft tissue** | 45 (6.2) | 20 (5.2) | 25 (7.4) |  |
| **Thyroid** | 155 (21.5) | 78 (20.3) | 77 (22.8) |  |
| **Years since treatment, mean (SD)** | 6.1 (4.6) | 5.5 (4.6) | 6.9 (4.5) | <0.01 |
| **< 2 years** | 129 (17.9) | 90 (23.4) | 39 (11.5) | <0.01 |
| **2 to < 5 years** | 196 (27.2) | 112 (29.2) | 84 (24.9) |  |
| **5 to < 10 years** | 280 (38.8) | 130 (33.8) | 150 (44.4) |  |
| **> 10 years** | 117 (16.2) | 52 (13.5) | 65 (19.2) |  |
| **Cancer recurrence** | 51 (7.1) | 26 (6.8) | 25 (7.4) | 0.74 |
| **Cancer Treatments** |
| **Radiation abdomen/pelvis**  | 37 (5.1) | 25 (6.5) | 12 (3.6) | 0.08 |
| **Radiation brain** | 10 (1.4) | 6 (1.5) | 4 (1.2) | 0.76 |
| **Total body irradiation** | 30 (4.1) | 17 (4.4) | 13 (3.8) | 0.69 |
| **Alkylating chemotherapy** | 369 (51.1) | 199 (51.8) | 170 (50.3) | 0.68 |
| **Cyclophosphamide equivalent dose** |  |  |  |  |
|  **None** | 442 (61.2) | 221 (57.6) | 221 (65.4) | 0.02 |
|  **< 7gm/m2** | 224 (31.0) | 136 (35.4) | 88 (26.0) |  |
|  **> 7gm/m2** | 56 (7.8) | 27 (7.0) | 29 (8.6) |  |
| **Gonadotoxicity risk group** |  |  |  |  |
|  **Low** | 202 (28.0) | 106 (31.4) | 96 (25.0) | 0.16 |
|  **Mod** | 432 (59.8) | 193 (57.1) | 239 (62.2) |  |
|  **High** | 88 (12.2) | 39 (11.5) | 49 (12.8) |  |
| **Stem cell transplant** | 47 (6.5) | 26 (6.8) | 21 (6.2) | 0.76 |
| **Unilateral oophorectomy** | 46 (6.4) | 25 (6.5) | 21 (6.2) | 0.87 |
| a Data expressed as n (%) unless otherwise noted;not all % add to 100 due to missing data |